Afficher la couverture 'Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. | Apetoh, Lionel' en grand format
/5

0 avis

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Archive ouverte

Apetoh, Lionel | Ghiringhelli, François | Tesniere, Antoine | Obeid, Michel | Ortiz, Carla | Criollo, Alfredo | Mignot, Grégoire | Maiuri, M Chiara | Ullrich, Evelyn | Saulnier, Patrick | Yang, Huan | Amigorena, Sebastian | Ryffel, Bernhard | Barrat, Franck J | Saftig, Paul | Levi, Francis | Lidereau, Rosette | Nogues, Catherine | Mira, Jean-Paul | Chompret, Agnès | Joulin, Virginie | Clavel-Chapelon, Françoise | Bourhis, Jean | André, Fabrice | Delaloge, Suzette | Tursz, Thomas | Kroemer, Guido | Zitvogel, Laurence

Edité par CCSD ; Nature Publishing Group -

Conventional cancer treatments rely on radiotherapy and chemotherapy. Such treatments supposedly mediate their effects via the direct elimination of tumor cells. Here we show that the success of some protocols for anticancer therapy depends on innate and adaptive antitumor immune responses. We describe in both mice and humans a previously unrecognized pathway for the activation of tumor antigen-specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs). During chemotherapy or radiotherapy, DCs require signaling through TLR4 and its adaptor MyD88 for efficient processing and cross-presentation of antigen from dying tumor cells. Patients with breast cancer who carry a TLR4 loss-of-function allele relapse more quickly after radiotherapy and chemotherapy than those carrying the normal TLR4 allele. These results delineate a clinically relevant immunoadjuvant pathway triggered by tumor cell death.

Consulter en ligne

Suggestions

Du même auteur

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Archive ouverte | Ghiringhelli, François | CCSD

International audience. The therapeutic efficacy of anticancer chemotherapies may depend on dendritic cells (DCs), which present antigens from dying cancer cells to prime tumor-specific interferon-gamma (IFN-gamma)-...

Calreticulin exposure dictates the immunogenicity of cancer cell death.

Archive ouverte | Obeid, Michel | CCSD

International audience. Anthracyclin-treated tumor cells are particularly effective in eliciting an anticancer immune response, whereas other DNA-damaging agents such as etoposide and mitomycin C do not induce immun...

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. A novel dendritic cell subset involved in tumor immunosurveillance

Archive ouverte | Taieb, Julien | CCSD

International audience. Systemic anticancer chemotherapy is immunosuppressive and mostly induces nonimmunogenic tumor cell death. Here, we show that even in the absence of any adjuvant, tumor cells dying in response...

Chargement des enrichissements...